Craig-Hallum Initiates Strong Buy on Spruce Biosciences with $140 Price Target as TA-ERT Advances Toward Approval
Spruce Biosciences has a rare disease drug (TA-ERT) showing strong results, FDA path clear, big sales and upside potential.
NOTRELOAD AI
Snap Stock Upgraded to Buy: Analyst Sees 77% Upside
Snap upgraded to Buy with 77% upside; analysts expect first profit, rising subscriptions, and stronger growth ahead.
Erasca Vows to Fight Revolution Medicines Patent Allegations – Stifel Stays Bullish
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
Critical Metals to Buy European Lithium for $835M — Secures 100% of Giant Tanbreez Rare Earth Project
Critical Metals to buy European Lithium for $835M, gaining full control of a major rare earth project and boosting cash.
POET Shares Plunge After Marvell Cancels All Celestial AI Orders
POET stock fell after Marvell canceled orders over confidentiality issues, but the company still sees growth in AI tech.
PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.